Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • medicalstarw medicalstarw Jul 22, 2013 1:16 PM Flag

    TBUFF (Mcap $19 M) Price:$0.39 // 7 Marketed Drugs & 1 NDA filing for Potential Blockbuster in 2014 & 1 Pending Approval

    This REAL Unknow and Low Float Gem has already 7 Products on the Market ,1 is Pending Approval and another 1 is close to US-NDA filing for Potential Blockbuster . The Market Cap of $19 M is really a BIG JOKE for a Company which hits $13 Million in revenue last year and growing fast

    Business Includes 7 Marketed Products Including Recently Launched CAMBIA .Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam® in Canada. MycoVa is currently pending regulatory approval in Canada.

    TGT $3-5 within 12 Months ..GLTA

    Tribute Pharma (TBUFF)

    Market Cap : $19 M
    Cash: $3 M
    Price:0.39

    Shares Out : 51 M ( 29 M shares are held by Management alone )

    All these Products below are available on the Market except Bezalip in USA and MycoVa which is pending Approval :

    Product Indication Geographic Right Market Size

    Bezalip® SR Mixed dyslipidemia US & Canada $20 B --- US-NDA filing in 2014

    NeoVisc® Osteoarthritis of the knee Global $1.4 B

    Soriatane® Moderate to severe psoriasis Canada $210 M

    Uracyst® Interstitial cystitis Global $151 M

    CAMBIA® Acute migraine headaches Canada $150 M

    Collatamp G® Prevention of post-operative infection Canada $20 M

    Gelfoam® Hemostatic device Canada $30 M

    MycoVa™ Nail fungus Canada $30 M -- Approval in early 2014
    --

 
AEGR
25.51-0.52(-2.00%)Mar 26 4:00 PMEDT